# A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS

> **NCT03290131** · PHASE3 · COMPLETED · sponsor: **RVL Pharmaceuticals, Inc.** · enrollment: 536 (actual)

## Conditions studied

- Multiple Sclerosis
- Spasticity, Muscle

## Interventions

- **DRUG:** Arbaclofen
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03290131
- **Lead sponsor:** RVL Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-28
- **Primary completion:** 2018-12-03
- **Final completion:** 2019-01-02
- **Target enrollment:** 536 (ACTUAL)
- **Last updated:** 2022-07-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03290131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03290131, "A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03290131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*